BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 27045512)

  • 61. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA
    Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PD-L1 Status in Refractory Lymphomas.
    Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
    PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma.
    Nam-Cha SH; Roncador G; Sanchez-Verde L; Montes-Moreno S; Acevedo A; Domínguez-Franjo P; Piris MA
    Am J Surg Pathol; 2008 Aug; 32(8):1252-7. PubMed ID: 18594468
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
    van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
    J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical Significance of
    Uhercik M; Sanders AJ; Owen S; Davies EL; Sharma AK; Jiang WG; Mokbel K
    Anticancer Res; 2017 Aug; 37(8):4249-4254. PubMed ID: 28739716
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Surfaceome of classical Hodgkin and non-Hodgkin lymphoma.
    Hofmann A; Thiesler T; Gerrits B; Behnke S; Sobotzki N; Omasits U; Bausch-Fluck D; Bock T; Aebersold R; Moch H; Tinguely M; Wollscheid B
    Proteomics Clin Appl; 2015 Aug; 9(7-8):661-70. PubMed ID: 26076441
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic value of PDL1 expression in pancreatic cancer.
    Birnbaum DJ; Finetti P; Lopresti A; Gilabert M; Poizat F; Turrini O; Raoul JL; Delpero JR; Moutardier V; Birnbaum D; Mamessier E; Bertucci F
    Oncotarget; 2016 Nov; 7(44):71198-71210. PubMed ID: 27589570
    [TBL] [Abstract][Full Text] [Related]  

  • 68. MUM-1 expression differentiates AITL with HRS-like cells from cHL.
    Huang W; Xie J; Xu X; Gao X; Xie P; Zhou X
    Int J Clin Exp Pathol; 2015; 8(9):11372-8. PubMed ID: 26617862
    [TBL] [Abstract][Full Text] [Related]  

  • 69. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
    Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
    Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas.
    Chen YT; Chadburn A; Lee P; Hsu M; Ritter E; Chiu A; Gnjatic S; Pfreundschuh M; Knowles DM; Old LJ
    Proc Natl Acad Sci U S A; 2010 Feb; 107(7):3093-8. PubMed ID: 20133697
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
    Tiemann M; Samoilova V; Atiakshin D; Buchwalow I
    BMC Res Notes; 2020 Mar; 13(1):139. PubMed ID: 32143684
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.
    Hao Y; Chapuy B; Monti S; Sun HH; Rodig SJ; Shipp MA
    Clin Cancer Res; 2014 May; 20(10):2674-83. PubMed ID: 24610827
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma.
    Aladily TN; Mansour A; Alsughayer A; Sughayer M; Medeiros LJ
    Ann Diagn Pathol; 2019 Jun; 40():72-76. PubMed ID: 31075666
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
    Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression.
    Kelley TW; Pohlman B; Elson P; Hsi ED
    Am J Clin Pathol; 2007 Dec; 128(6):958-65. PubMed ID: 18024321
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma.
    Calvo KR; Traverse-Glehen A; Pittaluga S; Jaffe ES
    Adv Anat Pathol; 2004 Sep; 11(5):227-38. PubMed ID: 15322489
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
    Steidl C; Lee T; Shah SP; Farinha P; Han G; Nayar T; Delaney A; Jones SJ; Iqbal J; Weisenburger DD; Bast MA; Rosenwald A; Muller-Hermelink HK; Rimsza LM; Campo E; Delabie J; Braziel RM; Cook JR; Tubbs RR; Jaffe ES; Lenz G; Connors JM; Staudt LM; Chan WC; Gascoyne RD
    N Engl J Med; 2010 Mar; 362(10):875-85. PubMed ID: 20220182
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.
    Greaves P; Clear A; Coutinho R; Wilson A; Matthews J; Owen A; Shanyinde M; Lister TA; Calaminici M; Gribben JG
    J Clin Oncol; 2013 Jan; 31(2):256-62. PubMed ID: 23045593
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
    Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
    Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Expression of FoxO3a in clinical cases of malignant lymphoma.
    Ikeda J; Tian T; Wang Y; Hori Y; Honma K; Wada N; Morii E
    Pathol Res Pract; 2013 Nov; 209(11):716-20. PubMed ID: 24021689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.